Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25313198 | 1.00 | ANPEP (0.57) | ANPEPHDAC3KMT2AMEN1HTT | |
| SCHEMBL25312585 | 0.89 | SMYD3 (0.55) | ANPEPSMYD3AKT1 | |
| SCHEMBL25312590 | 0.89 | SMYD3 (0.55) | ANPEPSMYD3AKT1 | |
| SCHEMBL25313543 | 0.88 | AKT1 (0.56) | ANPEPSMYD3AKT1 | |
| SCHEMBL25313541 | 0.88 | AKT1 (0.56) | ANPEPSMYD3AKT1 | |
| SCHEMBL25315485 | 0.88 | SMYD3 (0.65) | ANPEPNPC1SMYD3ALDH1A1LMNA | |
| SCHEMBL30376200 | 0.88 | SMYD3 (0.65) | ANPEPNPC1SMYD3ALDH1A1LMNA | |
| SCHEMBL18006588 | 0.88 | SMYD3 (0.65) | ANPEPNPC1SMYD3ALDH1A1LMNA | |
| SCHEMBL30375783 | 0.88 | SMYD3 (0.65) | ANPEPNPC1SMYD3ALDH1A1LMNA | |
| SCHEMBL25311225 | 0.86 | SMYD3 (0.52) | ANPEPSMYD3AKT1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212120-A1 | SMALL MOLECULE INHIBITORS OF GRK5 AND GRK5 SUBFAMILY MEMBERS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212120-A1 | SMALL MOLECULE INHIBITORS OF GRK5 AND GRK5 SUBFAMILY MEMBERS AND USES THEREOF | GRK5, GRK3, GRK4 | ANPEP 3978/4885HDAC3 382/4885KMT2A 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.